CH | EN

News

News Center

Company News

Industry News

Science Popularization

Video

Milestone Event: Mesoblast’s stem-cell drug receives FDA approval for market launch

2024-12-20

Recently, the U.S. Food and Drug Administration (FDA) announced its approval of Ryoncil (remestemcel), developed by Mesoblast, for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD) in children aged 2 months and older. This marks the first mesenchymal stromal cell (MSC) therapy globally to receive FDA approval.

This groundbreaking achievement has delivered tremendous encouragement and profound insights to the global stem cell industry, demonstrating that stem cell therapies—after rigorous scientific validation and regulatory approval—can indeed be commercialized to benefit patients. At the same time, it has injected Jiuzhitang Maker, a company dedicated to stem cell research and application, with renewed confidence and momentum.

Mesoblast Throughout the Ryoncil development process, the company faced countless experimental setbacks and rigorous regulatory scrutiny—but remained steadfast in its commitment to scientific rigor, continuously refining both production processes and clinical study designs. By collaborating closely with world-class experts, the team ultimately overcame critical technical challenges and regulatory hurdles, successfully bringing Ryoncil to market.

(Regarding Mesoblast's ups and downs—click to learn more. )

This This isn’t just a victory for Mesoblast—it’s a milestone for the entire stem cell industry. It inspires Jiuzhitang Maker and stem cell research firms around the globe to keep pushing forward, collectively advancing the development of stem cell therapies and contributing even more to the cause of human health.

In the future, Jiuzhitang Maker will draw on Mesoblast’s successful experience to accelerate its product development process and explore allogeneic human therapies. Bone marrow mesenchymal stem cells The application potential is immense—let’s strengthen and deepen our research collaborations, elevate our technological capabilities, and actively participate in the development of international standards. Our goal is to launch even more innovative cell therapy products that will benefit a growing number of patients. At the same time, we look forward to seeing more groundbreaking stem cell-based treatments emerge in the future, offering global patients safer and more effective treatment options—and together, building a brighter future for all.

Mesoblast's Lesson: Can Chinese Stem-Cell Companies Rise to the Challenge?

The kickoff meeting for the Jiuzhitang MakerWMS system project was successfully held.

Here is the title—h1 placeholder text

Online Message

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Business license